Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 1, 2011, Pages 148-159

  Devaney, James ^a,b   Stirzaker, Clare ^a,b   Qu, Wenjia ^a,b   Song, Jenny Z ^a,b   Statham, Aaron L ^a,b   Patterson, Kate I ^a,b   Horvath, Lisa G ^b,c   Tabor, Bruce ^b   Coolen, Marcel W ^a,b,d   Hulf, Toby ^a,b   Kench, James G ^b,e   Henshal, Susan M ^a,b   Pe Benito, Ruth ^b   Haynes, Anne Maree ^b   Mayor, Regina ^f,g   Peinado, Miguel A ^f,g   Sutherland, Robert L ^b   Clark, Susan J ^a,b  

^a Epigenetics Group   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Institut de Medicina Predictiva i Personalitzada del Cancer IMPPC   (Spain)

^g BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE P1; HISTONE H3; LYSINE; TUMOR MARKER;

ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 2Q; COHORT ANALYSIS; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; EN1 GENE; EPIGENETICS; GENE; GENE SILENCING; HUMAN; HUMAN CELL; INHBB GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SCTR GENE; SENSITIVITY AND SPECIFICITY;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOMES, HUMAN, PAIR 2; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLUTATHIONE S-TRANSFERASE PI; HOMEODOMAIN PROTEINS; HUMANS; INHIBIN-BETA SUBUNITS; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 78651448097     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0719     Document Type: Article

References (62)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
2. Fitzpatrick JM, Schulman C, Zlotta AR, Schroder FH. Prostate cancer: a serious disease suitable for prevention. BJU Int 2009; 103:864-70.
3. Cancer Research UK. Prostate cancer incidence statistics. [cited 2009 September]. Available from: http://info.cancerresearchuk.org/cancer-stats/types/ prostate/incidence/.
4. Short M, Harding J, Christensen E, Conley E. Cancer in Australia: an overview, 2006. Canberra, ACT: Australian Institute of Health and Welfare & Australasian Association of Cancer Registries; 2007.
5. National Cancer Institute Surveillance E, and End Results program. American Cancer Society, Cancer Facts & Figures 2004.
6. Enokida H, Shiina H, Urakami S, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 2005;116:174-81.
7. Holliday R. The inheritance of epigenetic defects. Science 1987; 238:163-70.
8. Horner MJ RL, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, et al., editors. SEER Cancer Statistics Review, 19752006. based on November 2008 SEER data submission, posted to the SEER web site, 2009. [cited 2009 September]. Available from: http://seer.cancer.gov/csr/1975-2006/.
9. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
10. McDavid K, Lee J, Fulton J, Tonita J, Thompson T. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-86.
11. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 2007;9:113-23.
12. Lin DW. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol 2009;27:315-21.
13. Schulz WA, Hoffmann MJ. Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 2009;19:172-80.
14. Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br J Cancer 2009;100:240-5.
15. Li LC. Epigenetics of prostate cancer. Front Biosci 2007;12:3377-97.
16. Maruyama R, Toyooka S, Toyooka K, et al. Aberrant promoter methy- lation profile of prostate cancers and its relationship to clinicopatho- logical features. Clin Cancer Res 2002;8:514-9.
17. Lee W, Morton R, Epstein J, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994;91:11733-7.
18. Okegawa T, Nutahara K, Higashihara E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 2010;17:466-75.
19. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG is land hypermethylation. Eur Urol 2004;46:698-708.
20. Goericke-Pesch S, Spang A, Schulz M, et al. Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant. Reprod Domest Anim 2009;44 Suppl2:302-8.
21. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009;150:3991-4002.
22. Yegnasubramanian S, Kowalski J, Gonzalgo M, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.
23. Jeronimo C, Henrique R, Hoque M, et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004;10:4010-4.
24. Zhang J, Liu L, Pfeifer G. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene 2004;23:2241-9.
25. Zhu X, Leav I, Leung Y, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004;164:2003-12.
26. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106:382-7.
27. Bastian P, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hyper-methylated gene loci. Clin Cancer Res 2005;11:4097-106.
28. Baden J, Green G, Painter J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009;182: 1186-93.
29. Frigola J, Song J, Stirzaker C, Hinshelwood R, Peinado M, Clark S. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006;38:540-9.
30. Mayor R, Casadome L, Azuara D, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer 2009;100:1534-9.
31. Song M, Song S, Ayad N, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6:129-37.
32. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004;64:3871-7.
33. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-705.
34. Clark S, Statham A, Stirzaker C, Molloy P, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006;1:2353-64.
35. Rand K, Ho T, Qu W, et al. Headloop suppression PCR and its application to selective amplification of methylated DNA sequences. Nucleic Acids Res 2005;33:e127.
36. Coolen M, Statham A, Gardiner-Garden M, Clark S. Genomic profiling of CpG methylation and allelic specificity using quantitative high- throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 2007;35:e119.
37. Horvath LG, Henshall SM, Kench JG, et al. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res 2004;10:615-25.
38. Liu P, Ramachandran S, Ali Seyed M, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006;66:4011-9.
39. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999;18:1313-24.
40. Guldberg P, Worm J, Gronbaek K. Profiling DNA methylation by melting analysis. Methods 2002;27:121-7.
41. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006;1:2353-64.
42. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6.
43. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009;69:1470-9.
44. Coolen MW, Stirzaker C, Song JZ, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010;12:235-46.
45. Moon R, Kohn A, De Ferrari G, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701.
46. Adamska M, MacDonald B, Sarmast Z, Oliver E, Meisler M. En1 and Wnt7a interact with Dkk1 during limb development in the mouse. Dev Biol 2004;272:134-44.
47. Tang C, Biemond I, Lamers C. Expression of peptide receptors in human endocrine tumours of the pancreas. Gut 1997;40:267-71.
48. Reis F, Luisi S, Carneiro M, etal. Activin, inhibin and thehuman breast. Mol Cell Endocrinol 2004;225:77-82.
49. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K, Gerber B. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. Oncol Rep 2005;13:81-8.
50. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-compo- nents and functional correlates. Genes Dev 2006;20:3215-31.
51. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-8.
52. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell Res 2007;17:850-7.
53. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
54. Gal-Yam EN, Egger G, Iniguez L, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci USA 2008;105: 12979-84.
55. Rosenbaum E, Hoque M, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-5.
56. Enokida H, Shiina H, Urakami S, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005;11:6582-8.
57. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;5:1886-901.
58. Florl AR, Steinhoff C, Muller M, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004;91:985-94.
59. Liu L, Yoon J, Dammann R, Pfeifer G. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002; 21:6835-40.
60. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.
61. Bastian P, Palapattu G, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-43.
62. Zhao W, Soejima H, Higashimoto K, et al. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 2005;137:431-40.